<DOC>
	<DOCNO>NCT01368315</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Phase I , Single-Center Study Efficacy Safety CT 327 Atopy Patch Test model .</brief_summary>
	<brief_title>CT 327 `` Atopy Patch Test '' Model</brief_title>
	<detailed_description>The study population include subject atopic dermatitis ( AD ) positive atopy patch test ( APT ) test study screen . Positive responder APT test enter treatment period ten day subject three test compound ( CT 327 , Placebo active comparator ) administer twice daily three test field mark patient 's back . A fourth test field act untreated control . A challenge relevant aeroallergen subject respond strongly , assess screening , take place Day 10 . Readings APT score perform 48 72 hr challenge subject end-of-study visit 2 week later . Local systemic tolerance CT327 assess study , addition potential absorption systemic circulation . The effect CT327 modulate immune response aeroallergens expression immunological inflammatory marker biopsy treat area also evaluate .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Age &gt; 18 &lt; 66 year age Able give inform consent Diagnosis atopic dermatitis positive atopy patch test least one follow ( Dermaphagoides pteronyssinus , cat dander , grass birch pollen ) Have concomitant dermatologic medical condition ( ) may interfere investigator 's ability evaluate subject 's response study drug Have positive response petrolatum Be immunecompromised Have clinically significant abnormal clinical laboratory test result Screening Have history malignancy except basal cell carcinoma skin . Have active intercurrent infection Have apply topical medication ( include corticosteroid , calcineurin inhibitor , topical H1 H2 antihistamine , topical antimicrobial , medicate topical agent ) herbal preparation area select treatment within 14 day prior study entry . Have receive antibiotic treatment within 1 week prior study entry Within 4 week prior study entry , receive systemic treatment atopic dermatitis ( include systemic corticosteroid , nonsteroidal , immunosuppressant , immunomodulating drug , treatment light ) . Have receive investigational drug part clinical study within last three month study entry . Have history hypersensitivity allergic reaction ingredient CT 327 formulation select active comparator polyethyleneglycol . If female , pregnant lactating , intend become pregnant study period If female , childbearing potential , take adequate contraception avoid pregnancy three month study . History drug , alcohol substance abuse factor limit ability cooperate comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>